Redwood City, CA22 days ago
The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner closely with Learning & Development, Corporate Communications, Legal, HR, regional compliance staff (U.S., Europe, and Asia), and business stakeholders to ensure effective deployment, localization, communication, and reinforcement of training programs.